Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB). We used imatinib to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene. After 3 months of treatment, we observed grade 4 hematologic toxicity and a lack of response.
Bastie
Jean-Noël
JN
Garcia
Isabel
I
Terré
Christine
C
Cross
Nicholas C P
NC
Mahon
Francois-Xavier
FX
Castaigne
Sylvie
S
D001549:Benzamides; D015415:Biomarkers; D002879:Chromosomes, Human, Pair 10 / Q000235:genetics / Q000648:ultrastructure; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics / Q000648:ultrastructure; D018450:Disease Progression; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015321:Gene Rearrangement; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007964:Leukocytosis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D050505:Mutant Proteins / Q000235:genetics*; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013156:Splenectomy; D013163:Splenomegaly / Q000209:etiology / Q000601:surgery; D013921:Thrombocytopenia / Q000139:chemically induced / Q000209:etiology; D014178:Translocation, Genetic; D017211:Treatment Failure
D001549:Benzamides; D015415:Biomarkers; D004791:Enzyme Inhibitors; C510875:H4-PDGFRB fusion protein, human; D050505:Mutant Proteins; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006918:Hydroxyurea